SCHEMBL1200200

SCHEMBL1200200

CC1C[CH]CC(C)N1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21979957 1.00
SCHEMBL21979884 1.00
SCHEMBL13069212 0.80 ALDH1A1 (0.31)
SCHEMBL2043434 0.69
SCHEMBL21979929 0.68
SCHEMBL13014851 0.67
SCHEMBL8747964 0.67
SCHEMBL10440033 0.67
SCHEMBL10134568 0.67
SCHEMBL254107 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200291018-A1 TAM KINASE INHIBITORS SYROS PHARMACEUTICALS, INC. (US) 2020-09-17 US claimed
EP-3652174-A1 TAM KINASE INHIBITORS Syros Pharmaceuticals, Inc. (US) 2020-05-20 EP claimed
WO-2019014513-A1 TAM KINASE INHIBITORS SYROS PHARMACEUTICALS, INC. (US) 2019-01-17 WO claimed
US-3931198-A CNS STIMULANTS OR DEPRESSANTS ABBOTT LABORATORIES (US) 1976-01-06 US claimed
CN-108707139-B Aminopyrimidine compound and preparation method and application thereof 北京鞍石生物科技有限责任公司 2021-04-06 CN disclosed
US-20200291018-A1 TAM KINASE INHIBITORS SYROS PHARMACEUTICALS, INC. (US) 2020-09-17 US disclosed
EP-3652174-A1 TAM KINASE INHIBITORS Syros Pharmaceuticals, Inc. (US) 2020-05-20 EP disclosed
EP-3634953-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2020-04-15 EP disclosed
WO-2019014513-A1 TAM KINASE INHIBITORS SYROS PHARMACEUTICALS, INC. (US) 2019-01-17 WO disclosed
WO-2018226622-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2018-12-13 WO disclosed
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-08-07 US disclosed
US-8748649-B2 Di-fluoro containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2014-06-10 US disclosed
WO-2005074904-A2 SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2005-08-18 WO disclosed
US-20050182096-A1 Haloalkyl containing compounds as cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-08-18 US disclosed
WO-2005058348-A1 USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC AXYS PHARMACEUTICALS, INC. (US) 2005-06-30 WO disclosed
US-6903117-B2 Indole derivatives for the treatment of osteoporosis NIKEM RESEARCH S.R.L. (IT) 2005-06-07 US disclosed
WO-2005028429-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed
US-20040010012-A1 Selective inhibitor of the biological activity of human osteoclast cells SMITHKLINE BEECHAM SPA 2004-01-15 US disclosed
US-20020173659-A1 Indole derivatives for the treatment of osteoporosis SMITH KLINE BEECHAM SPA 2002-11-21 US disclosed
US-3931198-A CNS STIMULANTS OR DEPRESSANTS ABBOTT LABORATORIES (US) 1976-01-06 US disclosed